1
Published 2013
Canadian Agency for Drugs and Technologies in Health
... of kidneys following cardiocirculatory death in order to support clinical practice decisions. The objective...

6
Published 2014
Canadian Agency for Drugs and Technologies in Health
... contact investigation following patient and staff exposure to a patient with TB in a hospital setting...

7
Published 2014
Canadian Agency for Drugs and Technologies in Health
... contact investigation following patient and staff exposure to a patient with TB in a hospital setting...

8
by Wells, George A.
Published 2017
CADTH
... of the benefits and harms associated with extended DAPT following PCI with stenting...

9
by Wells, George A.
Published 2017
CADTH
... of the benefits and harms associated with extended DAPT following PCI with stenting...

11
Published 2019
Canadian Agency for Drugs and Technologies in Health
... for six to 12 months following percutaneous coronary intervention (PCI) with stenting, with the aim...

12
by Wells, George A.
Published 2019
Canadian Agency for Drugs and Technologies in Health
..., or ticagrelor) together with ASA -- is routinely given following percutaneous coronary intervention (PCI...

13
by Wells, George A.
Published 2019
Canadian Agency for Drugs and Technologies in Health
..., or ticagrelor) together with ASA -- is routinely given following percutaneous coronary intervention (PCI...

14
Published 2019
Canadian Agency for Drugs and Technologies in Health
... for six to 12 months following percutaneous coronary intervention (PCI) with stenting, with the aim...

16
by Ho, Chuong, Cimon, Karen, Rabb, Danielle
Published 2013
Canadian Agency for Drugs and Technologies in Health
...) and CoreValve (Medtronic, Minneapolis, MN, US). The benefits of TAVR with up to one year follow-up were...

17
by Ho, Chuong, Cimon, Karen, Rabb, Danielle
Published 2013
Canadian Agency for Drugs and Technologies in Health
...) and CoreValve (Medtronic, Minneapolis, MN, US). The benefits of TAVR with up to one year follow-up were...

18
by Banerjee, Srabani, Kaunelis, David
Published 2017
Canadian Agency for Drugs and Technologies in Health
... and squamous carcinoma and the third report to follow will be on genital warts...

19
by Banerjee, Srabani, Kaunelis, David
Published 2017
Canadian Agency for Drugs and Technologies in Health
... and squamous carcinoma and the third report to follow will be on genital warts...

20
by Lee, Karen M.
Published 2011
Canadian Agency for Drugs and Technologies in Health
... viral transmission. The primary and secondary research questions for this work follow.1. Primary...